Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion

Sanofi SA and Regeneron Pharmaceuticals Inc. are expanding their 20-year partnership to develop and commercialize next-generation treatments, committing up to $8 billion. This includes a $1 billion upfront payment to Regeneron and potential milestone payouts of up to $7 billion. The companies will equally share development and commercialization expenses for new therapeutic programs, while maintaining the existing profit-sharing structure for their successful drug Dupixent, which saw sales increase by 37.6% to €5.154 billion in Q2 2023. Currently, Regeneron shares are down 3.31% at $733.14, and Sanofi shares are down 0.38% at $41.08.